Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine …

A Asatryan, N Meyer, M Scherbakov… - Human Vaccines & …, 2021 - Taylor & Francis
Full article: Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content
diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in …

[HTML][HTML] Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the Advisory Committee on Immunization …

FP Havers - MMWR. Morbidity and mortality weekly report, 2020 - cdc.gov
Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis
and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV). Hum Vaccin 2010;6:554–61. CrossRef…

Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines

P Pitisuttithum, J Dhitavat, C Sirivichayakul… - …, 2021 - thelancet.com
Background Recombinant pertussis vaccines inducing long-lasting immune responses could
help to control the rise in pertussis. We here report on persisting antibody responses 2 and …

[HTML][HTML] Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large …

KP Perrett, SA Halperin, T Nolan, AC Martínez… - Vaccine, 2020 - Elsevier
… ); Tdap, reduced-antigen-content diphtheria-tetanus-acellular … that administration of the
reduced-antigen-content Tdap … by the absence of statistical adjustments for multiple testing. …

[HTML][HTML] Immunogenicity and antibody persistence of diphteria-tetanus-acellular pertussis vaccination in adolescents and adults: A systematic review of the literature …

R Squeri, C Genovese - Journal of Preventive Medicine and …, 2020 - ncbi.nlm.nih.gov
… to choose a vaccine with multiple Bordetella pertussis components (Tdap3 or Tdap5). …
combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as …

[HTML][HTML] Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial

F Martinón-Torres, SA Halperin, T Nolan, B Tapiéro… - Vaccine, 2021 - Elsevier
… tetanus-reduced-antigen-content diphtheria-three-component acellular pertussis vaccine (…
In addition, because our study was descriptive and no adjustments for multiple comparisons …

[HTML][HTML] Fourteen years of the Pregnancy Registry on maternal immunisation with a reduced-antigen-content tetanus-diphtheria-acellular pertussis (Tdap) vaccine

A Kuznetsova, MA Ceregido, A Jourquin, L Campora… - Vaccine, 2022 - Elsevier
administration of one dose of the reduced-antigen-content tetanus-diphtheria-acellular pertussis
(… Reports of multiple exposures (ie, multiple administrations of Tdap-containing vaccine) …

[HTML][HTML] Immunogenicity and antibody persistence of diphteriatetanus-acellular pertussis vaccination in adolescents and adults: a systematic review of the literature …

R Squeri, C Genovese - J Prev Med Hyg, 2021 - ncbi.nlm.nih.gov
… to choose a vaccine with multiple Bordetella pertussis components (Tdap3 or Tdap5). …
combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as …

Antibody persistence to diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens, and Haemophilus influenzae type b following primary and first booster with …

N Wanlapakorn, N Sarawanangkoor… - Human Vaccines & …, 2024 - Taylor & Francis
Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular
pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV). Hum Vaccin. 2010;6(7):554–61. …

Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4–65 years of age: A …

I Aydin, M May, F Pisano, N Mpofu-Maetzig, L Grode… - Vaccine, 2023 - Elsevier
pertussis vaccine within the past 4 years (for children) or 5 years (for adolescents and adults,
except those who received tetanus- or Td-prone wound management … with multiple events …